Safety and immunogenicity of the group B streptococcus vaccine AlpN in a placebo-controlled double-blind phase 1 trial

Autor: Majela Gonzalez-Miro, Andrzej Pawlowski, Janne Lehtonen, Duojia Cao, Sara Larsson, Michael Darsley, Geoff Kitson, Per B. Fischer, Bengt Johansson-Lindbom

Publikováno v: iScience, Vol 26, Iss 3, Pp 106261- (2023)

Summary: Group B streptococcus (GBS) is a leading cause of life-threatening neonatal infections and subsets of adverse pregnancy outcomes. Essentially all GBS strains possess one allele of the alpha-like protein (Alp) family. A maternal GBS vaccine,

Externí odkaz: https://doaj.org/article/1443ab166a6e426da5ab679b8a8cbc05

Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against Group B Streptococcus in a randomised placebo-controlled double-blind phase 1 trial in healthy adult women

Autor: Bengt Johansson-Lindbom, Andrzej Pawlowski, David Bell, Michael J. Darsley, Geoff Kitson, Duojia Cao, Per Fischer

Publikováno v: Vaccine. 39(32)

Background Group B Streptococcus (GBS) is the leading cause of life-threatening infections in new-borns and may cause invasive disease, stillbirth and preterm delivery during pregnancy. While no licensed vaccine exists, maternal immunization might pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c9a66d1c1b942aca6e404fb434ad83e
https://pubmed.ncbi.nlm.nih.gov/34215454

A Double-Blind, Placebo-Controlled Trial to Assess Safety and Tolerability of (Thetanix) Bacteroides thetaiotaomicron in Adolescent Crohn's Disease

Autor: Richard K Russell, E. O'Herlihy, David C. Wilson, Paul Henderson, Rafeeq Muhammed, Lisa Gervais, Richard Hansen, Stephen Allen, Christos Tzivinikos, David Mullins, Geoff Kitson, Ian B. Jeffery, Ian R. Sanderson, John D. Weinberg

Publikováno v: Clinical and Translational Gastroenterology
Hansen, R, Sanderson, I R, Muhammed, R, Allen, S J, Tzivinikos, C, Henderson, P, Gervais, L, Jeffery, I B, Mullins, D, O'Herlihy, E A, Weinberg, J D, Kitson, G, Russell, R & Wilson, D C 2020, ' A double-blind, placebo-controlled trial to assess safety and tolerability of (Thetanix®) Bacteroides thetaiotaomicron in adolescent Crohn’s disease ', Clinical and translational gastroenterology, vol. 12, no. 1, e00287 . https://doi.org/10.14309/ctg.0000000000000287

INTRODUCTION: \ud Thetanix (gastroresistant capsules containing lyophilized Bacteroides thetaiotaomicron) is a live biotherapeutic, under development for Crohn's disease, that antagonizes transcription factor nuclear factor kappa B, reducing proinfla

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be0b66c149273247dbbbae9c878959b6
https://doi.org/10.14309/ctg.0000000000000287